This leads to the concern that in patients whose tumors harbor p53 mutations, inhibition of p53 degradation will result in increased levels of mutant p53 proteins, thereby aggravating its DNE and/or GOF effects and posing the danger that these compounds might even contribute to tumor growth and therapy resistance. Here, TP53 is linked to neoplasm.